Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Glycomimetics Inc (GLYC)

Glycomimetics Inc (GLYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,206
  • Shares Outstanding, K 64,450
  • Annual Sales, $ 10 K
  • Annual Income, $ -36,900 K
  • 60-Month Beta 2.30
  • Price/Sales 1,923.19
  • Price/Cash Flow N/A
  • Price/Book 0.51
Trade GLYC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.58
  • Most Recent Earnings $-0.14 on 03/27/24
  • Latest Earnings Date 05/09/24 [BMO]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 412.81% ( -16.77%)
  • Historical Volatility 502.08%
  • IV Percentile 91%
  • IV Rank 46.27%
  • IV High 820.87% on 10/11/23
  • IV Low 61.38% on 03/05/24
  • Put/Call Vol Ratio 0.66
  • Today's Volume 88
  • Volume Avg (30-Day) 3,117
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 66,853
  • Open Int (30-Day) 79,526

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.17
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2560 +2.27%
on 05/10/24
2.5700 -89.81%
on 04/11/24
-2.1882 (-89.31%)
since 04/10/24
3-Month
0.2560 +2.27%
on 05/10/24
3.3800 -92.25%
on 02/12/24
-3.0282 (-92.04%)
since 02/09/24
52-Week
0.2560 +2.27%
on 05/10/24
3.5299 -92.58%
on 01/23/24
-1.4982 (-85.13%)
since 05/10/23

Most Recent Stories

More News
GlycoMimetics: Q1 Earnings Snapshot

GlycoMimetics: Q1 Earnings Snapshot

GLYC : 0.2617 (-12.18%)
GlycoMimetics: Q4 Earnings Snapshot

GlycoMimetics: Q4 Earnings Snapshot

GLYC : 0.2617 (-12.18%)
GlycoMimetics: Q3 Earnings Snapshot

GlycoMimetics: Q3 Earnings Snapshot

GLYC : 0.2617 (-12.18%)
GlycoMimetics: Q2 Earnings Snapshot

GlycoMimetics: Q2 Earnings Snapshot

GLYC : 0.2617 (-12.18%)
GlycoMimetics: Q1 Earnings Snapshot

GlycoMimetics: Q1 Earnings Snapshot

GLYC : 0.2617 (-12.18%)
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 0.2617 (-12.18%)
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET.

GLYC : 0.2617 (-12.18%)
GlycoMimetics: Q4 Earnings Snapshot

GlycoMimetics: Q4 Earnings Snapshot

GLYC : 0.2617 (-12.18%)
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 0.2617 (-12.18%)
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m....

GLYC : 0.2617 (-12.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at...

See More

Key Turning Points

3rd Resistance Point 0.3313
2nd Resistance Point 0.3247
1st Resistance Point 0.3113
Last Price 0.2617
1st Support Level 0.2913
2nd Support Level 0.2847
3rd Support Level 0.2713

See More

52-Week High 3.5299
Fibonacci 61.8% 2.2793
Fibonacci 50% 1.8930
Fibonacci 38.2% 1.5066
Last Price 0.2617
52-Week Low 0.2560

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar